A recent NIDA-sponsored study found higher rates of NAS among males than among females. A second study found that, among infants whose mothers were treated with buprenorphine while pregnant, NAS was more severe among those whose mothers used other substances.
A single nucleotide polymorphism in the messenger RNA of the µ-opioid receptor gene was associated with patients’ responses to methadone treatment for opioid dependence.
Trial participants who were addicted to opioid painkillers and did not inject drugs stayed in treatment longer and achieved better outcomes than those who were addicted to heroin or injected drugs.
Two recent studies suggest that genotyping may enable clinicians to base therapies on individual patients’ potential responsiveness to opioid drugs’ therapeutic effects and vulnerability to their harmful effects.
